Update Breast Cancer 2019 Part 2-Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice

Beitrag in einer Fachzeitschrift
(Review-Artikel)


Details zur Publikation

Autorinnen und Autoren: Janni W, Schneeweiss A, Mueller V, Woeckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lueftner D, Belleville E, Schuetz F, Fasching P, Fehm TN, Kolberg HC, Ettl J
Zeitschrift: Geburtshilfe und Frauenheilkunde
Jahr der Veröffentlichung: 2019
Band: 79
Heftnummer: 3
Seitenbereich: 268-280
ISSN: 0016-5751


Abstract

The treatment of patients with advanced breast cancer has developed further in recent years. In addition to therapeutic progress in the established subgroups (hormone receptor and HER2 status), there are now therapies which are geared to individual molecular characteristics, such as PARP inhibitor therapy in BRCA-mutated patients. In addition to this, tests are being developed which are intended to establish addition-al markers within subgroups in order to predict the efficacy of a therapy. PI3K mutation testing in HER2-negative, hormonereceptor- positive tumours and PD-L1 testing of immune cells in triple-negative tumours are expected to become established in clinical practice in order to select patients for the respective therapies. With new therapeutic approaches, new adverse effects also appear. The management of these adverse effects, just as those of classical therapy (supportive therapy), is essential with the introduction of new treatments in order to preserve patients ' quality of life. Knowledge regarding measures to preserve and improve quality of life has significantly increased in recent years. Lifestyle factors should be taken into account, as should modern therapeutic methods. This review summarises the latest studies and publications and evaluates them in regard to the relevance for clinical practice.


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe
Nabieva, Naiba Dr. med.
Frauenklinik


Einrichtungen weiterer Autorinnen und Autoren

Centrum für Hämatologie und Onkologie Bethanien
Charité - Universitätsmedizin Berlin
ClinSol GmbH & Co.KG
Eberhard Karls Universität Tübingen
Marienhospital Bottrop
OncoConsult
Ruprecht-Karls-Universität Heidelberg
Technische Universität München (TUM)
Universitätsklinikum Düsseldorf
Universitätsklinikum Hamburg-Eppendorf
Universitätsklinikum Heidelberg
Universitätsklinikum Ulm
Universitätsklinikum Würzburg


Zitierweisen

APA:
Janni, W., Schneeweiss, A., Mueller, V., Woeckel, A., Lux, M.P., Hartkopf, A.D.,... Ettl, J. (2019). Update Breast Cancer 2019 Part 2-Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe und Frauenheilkunde, 79(3), 268-280. https://dx.doi.org/10.1055/a-0842-6661

MLA:
Janni, Wolfgang, et al. "Update Breast Cancer 2019 Part 2-Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice." Geburtshilfe und Frauenheilkunde 79.3 (2019): 268-280.

BibTeX: 

Zuletzt aktualisiert 2019-05-04 um 21:08